Determinants of risk factors of atherosclerosis in the postinfarction period: The Tallinn MI Study

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 66, Issue 3, 2006, Pages 191-199

  Aasvee, K ^a,b   Jauhiainen, M ^c   Kurvinen, E ^a,b   Tur, I ^a   Sundvall, J ^c   Roovere, T ^d   Baburin, A ^b  

^a Estonian Institute of Cardiology   (Estonia)

^b NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

Author keywords

ApoE polymorphism; Apolipoproteins; Behavioural risk factors; Fibrinogen; Lipids; Lipoprotein(a); Postinfarction period

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BIOLOGICAL MARKER; FIBRINOGEN; LIPID; LIPOPROTEIN; LIPOPROTEIN A;

ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ESTONIA; GENETIC POLYMORPHISM; GENETICS; HEART INFARCTION; HIGH RISK BEHAVIOR; HUMAN; HYPERLIPIDEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; OBESITY; PEDIGREE; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; THROMBOGENESIS; WAIST HIP RATIO;

ALLELES; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; ESTONIA; EXERCISE; HUMANS; HYPERLIPIDEMIAS; LINEAR MODELS; LIPIDS; LOGISTIC MODELS; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; RISK-TAKING; WAIST-HIP RATIO;

EID: 33745686153     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510600564881     Document Type: Article

References (52)

1. Health Statistics. Atlas on mortality in the European Union. Chapter 8. Cardiovascular diseases. Luxemburg: Office for Official Publications of the European Communities; 2003. http://europa.eu.int.
2. Baburin A, Gornoi K, Leinsalu M, Rahu M. Atlas of mortality in Estonia: Institute of Experimental and Clinical Medicine. Report of Grant EST0171 from the Swedish International Development Cooperation Agency. ISBN 9985-60-218-8. Estonia: Printall; 1997.
3. Porkka KVK, Taimela S, Kontula K, Lehtimäki T, Aalto- Setälä K, Åkerblom HK, et al. Variability gene effects of DNA polymorphisms at the apoB, apo A I/C III and apoE loci on serum lipids: the Cardiovascular Risk in Young Finns Study. Clin Genet 1994;45:113-21.
4. Dammerman M, Breslow JL. Genetic basis of lipoprotein disorders. Circulation 1995;91:505-12.
5. Weisgraber KH, Rall SC, Mahley RW. Human E apolipoprotein heterogeneity: cysteine-arginine interchanges in the amino acid sequence of the the apo E isoforms. J Biol Chem 1981;256:9077-83.
6. Ehnholm C, Lukka M, Kuusi T, Nikkilä E, Utermann G. Apolipoprotein E polymorphism in a Finnish population: gene frquencies and relation to lipoprotein concentration. J Lipid Res 1986;27:227-35.
7. Haddy N, De Backer D, Chemaly MM, Maurice M, Ehnholm C, Evans A, et al. The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: results from Apo Europe. Eur J Hum Genet 2002;10:841-50.
8. Wilson PWF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. A meta analysis. Arterioscler Thromb Vasc Biol 1996;16:1250-5.
9. Chapman M J, Huby T, Nigon F, Thillet J. Lipoprotein (a): implication in atherothrombosis [review]. Atherosclerosis 1994;110 Suppl: S69-75.
10. McLean JW, Tomlison JE, Kuang W, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;300:132-7.
11. Boerwinkle E, Leffert CC, Lin J, Lacner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90 % of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-60.
12. Kostner GM, Avogaro P, Gazzolato G, Marth E, Bittolo-Bon G, Quinci GB. Lipoprotein Lp(a) and the risk of myocardial infarction. Atherosclerosis 1981;38:51-61.
13. Dahlen GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994;108:111-26.
14. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Mänttäri M, Manninen V, et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89:59-67.
15. Klausen IC, Beisiegel U, Menzel H-J, Rosseneu M, Nicaud V, Faergeman O, on behalf of the EARS Group. Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction. Arterioscler Thromb Vasc Biol 1995;15:1001-8.
16. Grimby G. Physical activity and muscle training in the elderly. Acta Med Scand 1986; Suppl 711: 233-7.
17. Kostner GM, Avogaro P, Bittolo Bon G, Cazzolato G, Quinci GB. Determination of high-density lipoproteins: screening methods compared. Clin Chem 1979;25:939-42.
18. Friedewald WT, Levy RJ, Fredricson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
19. Havekes LM, De Knijff P, Beisiegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987;28:455-63.
20. Hixon JE, Vernier DT. Restriction isotyping of human apoliporotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.
21. Sundvall J, Sulonen G-B, Hiltunen O, Kiuru J, Pursiainen M, Jauhiainen M. Comparison of a new immunoturbidimetric assay of human serum lipoprotein(a) to the ELISA and the IRMA methods. Scand J Clin Lab Invest 1995;55:171-80.
22. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemotol 1957;17:237-47.
23. Stata Base Reference Manual (4 volumes). Stata Press; 2003. 1-881228-69-X Vol. 1-4, 1837 pp.
24. MedCalc for Windows. Statistics for Biomedical Research. Belgium: Frank Schoonjans; ©1993-1999.
25. Assmann G, Schulte H. European lipid guidelines: therapeutic recommendations. Am J Cardiol 1989;63:53H-5H.
26. Luc G, Bard JM, Arveiler D, Evans A, Cambou JP, Bingham A, et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 1994;14:1412-9.
27. Parra HJ, Arveiler D, Evans A, Cambou JP, Amouyel P, Bingham A, et al. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992;12:701-7.
28. Mediene-Benchekor S, Brousseau T, Richard F, Benhamamouch S, Amouyel P, the ECTIM Study Group. Blood lipid concentrations and risk of myocardial infarction. Lancet 2001;358:1064-5.
29. Walldius G, Junger I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS Study): a prospective study. Lancet 2001;358:2026-33.
30. Rosseneu M, Fruchart JC, Bard JM, Nicaud V, Vinaimont N, Cambien F, et al. Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. Circulation 1994;86:1967-73.
31. Hallman DM, Boerwinkle E, Saha N, Sandholzer C, Menzel HJ, Csázár A, et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991;49:338-49.
32. VanBockxmeer FM, Mamotte CDS. Apolipoprotein ε4 homozygosity in young men with coronary heart disease. Lancet 1992;340:879-80.
33. Liu S, Ma J, Ridker PM, Breslow JL, Stampfer MJ. A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 2003;166:323-9.
34. Scaglione L, Bergerone S, Gambio R, Imazio M, Macchia G, Cravetto A, et al. Role of lipid apolipoprotein levels and apolipoprotein E genotype in young Italian patients with myocardial infarction. Nutr Metab Cardiovasc Dis 1999;9:118-24.
35. Humphries SE, Ordovas JM. Genetics and atherosclerosis: broadening the horizon. Atherosclerosis 2001;154:517-9.
36. Rantala M, Savolainen J, Kervinen K, Kesäniemi YA. Apolipoprotein E phenotype and diet-induced alteration in blood pressure. Am J Clin Nutr 1997;65:543-50.
37. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day INM, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001;358:115-9.
38. Karvonen J, Kauma H, Kervinen K, Ukkola O, Rantala M, Päivänsalo M, et al. Apolipoprotein E polymorphism affects carotid artery atherosclerosis in smoking hypertensive men. J Hypertension 2002;20:2371-8.
39. Humphries SE, Ridker PM, Talmud PJ. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation? Arterioscl Thromb Vasc Biol 2004;24:628-36.
40. Saarelainen S, Lehtimäki T, Nikkilä M, Solakivi T, Nieminen MM, Jaakkola O. Association between apolipoprotein E alleles and autoantibodies against oxidised low-density lioprotein. Clin Chem Lab Med 2000;38:477-8.
41. Ranallo RF, Rhodes EC. Lipid metabolism during exercise [review]. Sports Med 1998;26:29-42.
42. Berg A, Halle M, Franz I, Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials [review]. Eur J Med Res 1997;2:259-64.
43. Kharb S, Singh GP. Effect of smoking on lipid profile, lipid peroxidation and antioxidant status in normal subjects and in patients during and after acute myocardial infarction. Clin Chim Acta 2000;302:213-9.
44. Langer RD, Criqui MH, Reed DM. Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. Circulation 1992;85:910-5.
45. Dreon MD, Krauss RM. Alcohol, lipids, and lipoproteins. In Zahkari S, Wassef M, editors. Alcohol and the cardiovascular system. Research Monograph No. 31. National Institute on Alcohol Abuse and Alcoholism. Washington: Government Printing Office; 1996. pp. 369-91.
46. Temelkova-Kurktschiev T, Henkel E, Koehler C, Hanefeld M. Light-to-moderate alcohol consumption, risk factor profile and early atherosclerosis: the RIAD Study. Atherosclerosis 2001;156:239-40.
47. Aasvee K, Kurvinen E, Jordania R, Jauhiainen M, Sundvall J. Lipoprotein parameters in relation to other risk factors of atherosclerosis in adults and newborns: Tallinn Young Family Study. Scand J Clin Lab Invest 2004;64:245-54.
48. Reinhart WH. Fibrinogen: marker or mediator of vascular disease? [review]. Vasc Med 2003;8:211-6.
49. Lowe GDO. Recent progress in the epidemiology of haemostatic factors. In Jacotot BMathé D, Fruchart J-D, editors. Atherosclerosis XI. Singapore: Elsevier Science; 1998. pp. 57-62.
50. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989;78:145-50.
51. Foody JAM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein(a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000;153:445-51.
52. Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, et al. The Yin and Yang of oxidation of the fatty streak. A review based on the 1994 Georg Luman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996;16:831-42.